Comparative Pharmacology
Head-to-head clinical analysis: ISMO versus NITROLINGUAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISMO versus NITROLINGUAL.
ISMO vs NITROLINGUAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isosorbide mononitrate is a nitrate that dilates coronary arteries and peripheral veins. It acts by releasing nitric oxide, which activates guanylate cyclase, increasing cGMP levels, leading to smooth muscle relaxation and vasodilation.
Nitroglycerin is converted to nitric oxide (NO), which activates guanylyl cyclase, increasing cGMP levels in vascular smooth muscle. This leads to dephosphorylation of myosin light chains, causing vasodilation. It predominantly dilates venous capacitance vessels, reducing preload, and to a lesser extent dilates arterioles, reducing afterload.
20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to minimize nitrate tolerance.
1 to 2 sprays (0.4 mg/spray) sublingually at onset of angina, may repeat every 5 minutes up to 3 doses; prophylactic use: 1 spray 5-10 minutes before activity.
None Documented
None Documented
Clinical Note
moderateVismodegib + Digoxin
"Vismodegib may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateVismodegib + Digitoxin
"Vismodegib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateVismodegib + Deslanoside
"Vismodegib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateVismodegib + Acetyldigitoxin
"Vismodegib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 5-6 hours. In elderly patients or those with hepatic impairment, half-life may be prolonged (up to 8-10 hours), warranting dose adjustment.
2-3 minutes for sublingual nitroglycerin; rapid decline due to extensive first-pass metabolism and high clearance (30-40 L/min). Clinical context: extremely short half-life necessitates continuous or frequent dosing for sustained effect.
Primarily renal; 80-90% of the dose is excreted as inactive metabolites (isosorbide mononitrate and isosorbide dinitrate) in urine. Less than 1% is excreted unchanged. Fecal excretion is minimal.
Renal (primarily as glucuronide conjugates and denitrated metabolites): ~60-80%; Fecal: ~20-40%; Biliary: negligible. Less than 1% excreted unchanged.
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator